Skip to main content
. 2019 Feb 5;11(2):183. doi: 10.3390/cancers11020183

Figure 1.

Figure 1

Figure 1

Targeting melanoma Ag to CD169 results in specific T cell responses in mice. Intravenous immunization with 1 µg Ab:Ag conjugates in the presence of 25 µg anti-CD40 Ab and 25 µg Poly(I:C). (A) Percentage of IFNγ producing CD8+ T cells after 5 h in vitro restimulation with Trp2 peptide 7 days after immunization with Trp2:Ab conjugates. (B–C) Percentage of IFNγ producing CD8+ T cells after 5 h in vitro restimulation with (B) human gp100 peptide or (C) mouse gp100 peptide 7 days after immunization with human gp100:Ab conjugates. (D) Percentage of CD8+ T cells binding H2-Db tetramers 7 days after immunization with human gp100:Ab conjugates. Combined data of two experiments with 4–6 mice per group with one representative dotplot of each group is shown for all figures except for C which is one experiment with 6 mice per group. Statistical analysis one-way ANOVA with Sidak’s multiple comparison test * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.